Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

Novartis Ag (NYSE: NVS) Q3 2024 Earnings Call Oct 29, 2024, 9:00 a.m. ET Good morning and good afternoon, and welcome to the ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Novartis’ challenge to Pfizer’s blockbuster breast cancer drug, Ibrance, is building momentum, after the US regulator granted it a fast review. The US Food and Drug Administration granted the ...

Reports Q3 revenue $12.82B, consensus $12.76B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another quarter of ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...